Raj Shah
Concepts (349)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cholangiopancreatography, Endoscopic Retrograde | 47 | 2026 | 219 | 10.260 |
Why?
| | Endoscopy, Digestive System | 24 | 2026 | 140 | 7.230 |
Why?
| | Pancreatic Ducts | 23 | 2025 | 81 | 6.950 |
Why?
| | Pancreatic Diseases | 14 | 2024 | 66 | 4.740 |
Why?
| | Pancreatitis, Chronic | 12 | 2024 | 62 | 4.450 |
Why?
| | Calculi | 8 | 2022 | 16 | 3.870 |
Why?
| | Bile Duct Neoplasms | 13 | 2021 | 127 | 3.360 |
Why?
| | Endosonography | 25 | 2024 | 157 | 3.340 |
Why?
| | Stents | 21 | 2025 | 556 | 3.200 |
Why?
| | Lithotripsy | 11 | 2024 | 49 | 3.180 |
Why?
| | Cholangitis, Sclerosing | 8 | 2022 | 60 | 2.790 |
Why?
| | Pancreatic Neoplasms | 20 | 2024 | 918 | 2.530 |
Why?
| | Cholangiocarcinoma | 7 | 2021 | 105 | 2.410 |
Why?
| | Bile Ducts | 10 | 2025 | 67 | 2.020 |
Why?
| | Drainage | 10 | 2024 | 185 | 1.980 |
Why?
| | Bile Ducts, Intrahepatic | 5 | 2021 | 62 | 1.900 |
Why?
| | Constriction, Pathologic | 16 | 2025 | 248 | 1.830 |
Why?
| | Cholestasis | 8 | 2025 | 219 | 1.820 |
Why?
| | Biliary Tract Surgical Procedures | 4 | 2021 | 28 | 1.750 |
Why?
| | Endoscopy, Gastrointestinal | 12 | 2023 | 237 | 1.710 |
Why?
| | Gallstones | 5 | 2026 | 34 | 1.490 |
Why?
| | Laser Therapy | 2 | 2025 | 135 | 1.290 |
Why?
| | Pancreatic Pseudocyst | 5 | 2024 | 18 | 1.260 |
Why?
| | Microscopy, Confocal | 8 | 2021 | 321 | 1.210 |
Why?
| | Pancreas | 6 | 2021 | 341 | 1.180 |
Why?
| | Biliary Tract Diseases | 4 | 2016 | 33 | 1.180 |
Why?
| | Endoscopes | 3 | 2017 | 17 | 1.050 |
Why?
| | Aged | 53 | 2026 | 25850 | 1.030 |
Why?
| | Middle Aged | 61 | 2026 | 35762 | 1.010 |
Why?
| | Treatment Outcome | 31 | 2025 | 11643 | 0.990 |
Why?
| | Carcinoma, Pancreatic Ductal | 5 | 2016 | 291 | 0.960 |
Why?
| | Retrospective Studies | 31 | 2025 | 17009 | 0.900 |
Why?
| | Adenocarcinoma | 7 | 2023 | 927 | 0.850 |
Why?
| | Pancreatitis | 5 | 2024 | 142 | 0.840 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 7 | 2019 | 59 | 0.830 |
Why?
| | Endoscopy | 4 | 2015 | 315 | 0.830 |
Why?
| | Endoscopes, Gastrointestinal | 8 | 2013 | 13 | 0.830 |
Why?
| | Humans | 110 | 2026 | 144261 | 0.810 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2023 | 27 | 0.800 |
Why?
| | Duodenal Neoplasms | 1 | 2023 | 26 | 0.800 |
Why?
| | Ampulla of Vater | 1 | 2023 | 39 | 0.790 |
Why?
| | Choledochal Cyst | 2 | 2020 | 17 | 0.780 |
Why?
| | Laparoscopy | 4 | 2021 | 475 | 0.770 |
Why?
| | Male | 66 | 2026 | 72035 | 0.760 |
Why?
| | Female | 68 | 2026 | 77976 | 0.750 |
Why?
| | Hepatic Encephalopathy | 1 | 2022 | 25 | 0.750 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2016 | 76 | 0.740 |
Why?
| | Catheterization | 8 | 2024 | 183 | 0.730 |
Why?
| | Gastrointestinal Tract | 1 | 2025 | 208 | 0.730 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2022 | 38 | 0.720 |
Why?
| | Adenoma | 2 | 2023 | 218 | 0.720 |
Why?
| | Pancreatectomy | 3 | 2021 | 285 | 0.710 |
Why?
| | Hypertension, Portal | 1 | 2022 | 66 | 0.710 |
Why?
| | Cholangitis | 1 | 2022 | 23 | 0.710 |
Why?
| | End Stage Liver Disease | 1 | 2022 | 94 | 0.670 |
Why?
| | Calcinosis | 2 | 2019 | 233 | 0.640 |
Why?
| | Cytodiagnosis | 1 | 2020 | 31 | 0.640 |
Why?
| | Intestine, Small | 2 | 2019 | 166 | 0.600 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2020 | 322 | 0.590 |
Why?
| | Adult | 37 | 2026 | 40262 | 0.560 |
Why?
| | Lithotripsy, Laser | 2 | 2015 | 4 | 0.560 |
Why?
| | Aged, 80 and over | 18 | 2025 | 8243 | 0.540 |
Why?
| | Quality of Life | 4 | 2024 | 3166 | 0.530 |
Why?
| | Aneurysm, False | 1 | 2018 | 45 | 0.530 |
Why?
| | Artificial Intelligence | 1 | 2022 | 365 | 0.520 |
Why?
| | Foreign Bodies | 1 | 2018 | 107 | 0.510 |
Why?
| | Prospective Studies | 23 | 2024 | 7970 | 0.510 |
Why?
| | Disposable Equipment | 1 | 2017 | 24 | 0.510 |
Why?
| | Liver Neoplasms | 1 | 2023 | 780 | 0.510 |
Why?
| | Polyethylene | 1 | 2016 | 17 | 0.470 |
Why?
| | Biopsy | 6 | 2018 | 1075 | 0.470 |
Why?
| | Follow-Up Studies | 13 | 2025 | 5389 | 0.470 |
Why?
| | Gallbladder Diseases | 1 | 2015 | 11 | 0.460 |
Why?
| | Gastroenterology | 4 | 2019 | 188 | 0.450 |
Why?
| | Gastrointestinal Diseases | 5 | 2022 | 216 | 0.440 |
Why?
| | Pancreatic Juice | 1 | 2014 | 3 | 0.440 |
Why?
| | Learning Curve | 5 | 2019 | 70 | 0.430 |
Why?
| | Sphincterotomy, Endoscopic | 4 | 2019 | 29 | 0.420 |
Why?
| | Biomarkers, Tumor | 2 | 2014 | 1313 | 0.420 |
Why?
| | CA-19-9 Antigen | 1 | 2014 | 31 | 0.410 |
Why?
| | Metals | 4 | 2023 | 142 | 0.410 |
Why?
| | Sensitivity and Specificity | 9 | 2021 | 1983 | 0.410 |
Why?
| | Postoperative Complications | 3 | 2022 | 2916 | 0.390 |
Why?
| | Cholestasis, Intrahepatic | 1 | 2013 | 29 | 0.390 |
Why?
| | Hemorrhage | 1 | 2018 | 809 | 0.370 |
Why?
| | Ultrasonography, Interventional | 3 | 2022 | 160 | 0.370 |
Why?
| | Pancreatitis, Acute Necrotizing | 2 | 2023 | 14 | 0.370 |
Why?
| | Predictive Value of Tests | 7 | 2017 | 2111 | 0.350 |
Why?
| | Anastomosis, Roux-en-Y | 2 | 2022 | 26 | 0.340 |
Why?
| | Liver Diseases | 1 | 2014 | 304 | 0.340 |
Why?
| | Biliary Tract Neoplasms | 3 | 2016 | 30 | 0.320 |
Why?
| | Young Adult | 9 | 2025 | 13990 | 0.320 |
Why?
| | Clinical Competence | 5 | 2019 | 1241 | 0.320 |
Why?
| | Foreign-Body Migration | 2 | 2006 | 32 | 0.290 |
Why?
| | Natural Orifice Endoscopic Surgery | 3 | 2018 | 34 | 0.280 |
Why?
| | Needles | 3 | 2019 | 62 | 0.280 |
Why?
| | Pancreatic Cyst | 3 | 2018 | 50 | 0.280 |
Why?
| | B7-1 Antigen | 1 | 2008 | 55 | 0.270 |
Why?
| | Gastrointestinal Hemorrhage | 2 | 2008 | 136 | 0.270 |
Why?
| | Video Recording | 4 | 2016 | 211 | 0.260 |
Why?
| | Fluorouracil | 4 | 2020 | 235 | 0.260 |
Why?
| | Bile Ducts, Extrahepatic | 2 | 2020 | 20 | 0.250 |
Why?
| | Gallbladder | 2 | 2022 | 15 | 0.250 |
Why?
| | Dilatation | 2 | 2018 | 72 | 0.250 |
Why?
| | Abdominal Pain | 4 | 2023 | 146 | 0.240 |
Why?
| | Adolescent | 11 | 2025 | 22281 | 0.240 |
Why?
| | Cholelithiasis | 3 | 2015 | 36 | 0.230 |
Why?
| | Autonomic Nerve Block | 1 | 2024 | 9 | 0.220 |
Why?
| | Celiac Plexus | 1 | 2024 | 6 | 0.220 |
Why?
| | Hemostatic Techniques | 1 | 2005 | 51 | 0.220 |
Why?
| | Indomethacin | 1 | 2024 | 76 | 0.210 |
Why?
| | Catheters | 2 | 2015 | 75 | 0.210 |
Why?
| | Peritoneal Neoplasms | 1 | 2005 | 103 | 0.210 |
Why?
| | Guanidines | 1 | 2023 | 41 | 0.210 |
Why?
| | Tumor Suppressor Protein p53 | 1 | 2008 | 529 | 0.200 |
Why?
| | Ambulatory Care Facilities | 1 | 2006 | 264 | 0.200 |
Why?
| | Equipment Design | 9 | 2013 | 530 | 0.200 |
Why?
| | Esters | 1 | 2023 | 78 | 0.200 |
Why?
| | Prosthesis Implantation | 2 | 2019 | 153 | 0.190 |
Why?
| | Cholecystitis, Acute | 1 | 2022 | 24 | 0.190 |
Why?
| | Self Expandable Metallic Stents | 1 | 2022 | 17 | 0.190 |
Why?
| | Pain | 3 | 2022 | 777 | 0.180 |
Why?
| | Pain Measurement | 1 | 2024 | 552 | 0.180 |
Why?
| | Choledochostomy | 1 | 2022 | 10 | 0.180 |
Why?
| | Plastics | 2 | 2022 | 47 | 0.180 |
Why?
| | Analgesics, Opioid | 2 | 2024 | 1131 | 0.180 |
Why?
| | Multiple Myeloma | 1 | 2005 | 291 | 0.180 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 338 | 0.170 |
Why?
| | Multivariate Analysis | 3 | 2021 | 1533 | 0.170 |
Why?
| | Antimetabolites, Antineoplastic | 2 | 2020 | 105 | 0.170 |
Why?
| | Multicenter Studies as Topic | 1 | 2022 | 402 | 0.170 |
Why?
| | United States | 9 | 2017 | 15876 | 0.160 |
Why?
| | Tegafur | 1 | 2020 | 12 | 0.160 |
Why?
| | Lasers | 1 | 2021 | 132 | 0.160 |
Why?
| | Oxonic Acid | 1 | 2020 | 13 | 0.160 |
Why?
| | Fluoroscopy | 4 | 2026 | 176 | 0.160 |
Why?
| | Logistic Models | 3 | 2021 | 2104 | 0.150 |
Why?
| | Dissection | 2 | 2018 | 56 | 0.150 |
Why?
| | Living Donors | 1 | 2022 | 280 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2022 | 1705 | 0.150 |
Why?
| | Fiducial Markers | 1 | 2019 | 9 | 0.150 |
Why?
| | Urinary Calculi | 1 | 2019 | 10 | 0.150 |
Why?
| | Hydrogen Peroxide | 1 | 2021 | 336 | 0.150 |
Why?
| | Carcinoma, Squamous Cell | 1 | 2004 | 641 | 0.150 |
Why?
| | Carcinoembryonic Antigen | 2 | 2018 | 38 | 0.150 |
Why?
| | ROC Curve | 2 | 2018 | 612 | 0.150 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2019 | 39 | 0.150 |
Why?
| | Severity of Illness Index | 2 | 2022 | 2917 | 0.150 |
Why?
| | Reproducibility of Results | 4 | 2019 | 3403 | 0.140 |
Why?
| | Anastomosis, Surgical | 1 | 2019 | 157 | 0.140 |
Why?
| | Risk Factors | 6 | 2024 | 10699 | 0.140 |
Why?
| | Lasers, Solid-State | 1 | 2018 | 22 | 0.140 |
Why?
| | Journal Impact Factor | 1 | 2018 | 29 | 0.140 |
Why?
| | Cystadenoma, Serous | 1 | 2018 | 18 | 0.130 |
Why?
| | Gastric Outlet Obstruction | 1 | 2017 | 12 | 0.130 |
Why?
| | Cholecystectomy, Laparoscopic | 1 | 2018 | 54 | 0.130 |
Why?
| | Fiber Optic Technology | 2 | 2015 | 24 | 0.130 |
Why?
| | Hospitals, University | 1 | 2018 | 176 | 0.130 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1487 | 0.130 |
Why?
| | Gastrointestinal Neoplasms | 2 | 2008 | 70 | 0.130 |
Why?
| | Parkinsonian Disorders | 1 | 2017 | 43 | 0.130 |
Why?
| | Urinary Incontinence | 1 | 2017 | 64 | 0.130 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2023 | 1137 | 0.130 |
Why?
| | Narrow Band Imaging | 1 | 2016 | 14 | 0.130 |
Why?
| | Feasibility Studies | 4 | 2018 | 1087 | 0.120 |
Why?
| | Education, Medical, Graduate | 2 | 2019 | 557 | 0.120 |
Why?
| | Neuroendocrine Tumors | 1 | 2018 | 112 | 0.120 |
Why?
| | Regression Analysis | 1 | 2018 | 998 | 0.120 |
Why?
| | Reoperation | 1 | 2019 | 629 | 0.120 |
Why?
| | Time Factors | 3 | 2019 | 7155 | 0.120 |
Why?
| | Gastric Bypass | 1 | 2017 | 124 | 0.120 |
Why?
| | Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 28 | 0.120 |
Why?
| | Neoplasm Staging | 6 | 2013 | 1461 | 0.120 |
Why?
| | Cystadenoma, Mucinous | 1 | 2015 | 11 | 0.110 |
Why?
| | Periodicals as Topic | 1 | 2018 | 203 | 0.110 |
Why?
| | Cystadenocarcinoma, Mucinous | 1 | 2015 | 12 | 0.110 |
Why?
| | Pathology, Clinical | 1 | 2015 | 29 | 0.110 |
Why?
| | Radio Waves | 1 | 2015 | 28 | 0.110 |
Why?
| | Single-Blind Method | 1 | 2016 | 311 | 0.110 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 355 | 0.110 |
Why?
| | Pancreaticoduodenectomy | 1 | 2016 | 135 | 0.110 |
Why?
| | Incidence | 2 | 2018 | 2870 | 0.100 |
Why?
| | Europe | 1 | 2014 | 412 | 0.100 |
Why?
| | Tertiary Care Centers | 1 | 2014 | 187 | 0.100 |
Why?
| | Double-Balloon Enteroscopy | 1 | 2013 | 1 | 0.100 |
Why?
| | Disinfection | 2 | 2018 | 129 | 0.100 |
Why?
| | Length of Stay | 1 | 2019 | 1335 | 0.100 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 2 | 2013 | 1953 | 0.100 |
Why?
| | Databases, Factual | 1 | 2018 | 1484 | 0.090 |
Why?
| | Cyst Fluid | 2 | 2018 | 20 | 0.090 |
Why?
| | Colonoscopy | 2 | 2018 | 260 | 0.090 |
Why?
| | Academic Medical Centers | 2 | 2017 | 545 | 0.090 |
Why?
| | Carcinoma | 1 | 2013 | 227 | 0.090 |
Why?
| | Technology Assessment, Biomedical | 2 | 2008 | 44 | 0.080 |
Why?
| | Chemoradiotherapy | 1 | 2013 | 237 | 0.080 |
Why?
| | Deoxycytidine | 2 | 2013 | 221 | 0.080 |
Why?
| | Biopsy, Fine-Needle | 2 | 2008 | 68 | 0.080 |
Why?
| | Cohort Studies | 2 | 2014 | 5935 | 0.080 |
Why?
| | Esophageal Neoplasms | 2 | 2005 | 346 | 0.080 |
Why?
| | Referral and Consultation | 2 | 2016 | 847 | 0.080 |
Why?
| | Catheter Ablation | 1 | 2015 | 353 | 0.080 |
Why?
| | Antibiotic Prophylaxis | 1 | 2012 | 129 | 0.080 |
Why?
| | Parkinson Disease | 1 | 2017 | 600 | 0.080 |
Why?
| | Radiography | 1 | 2013 | 842 | 0.080 |
Why?
| | Child | 4 | 2018 | 22537 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2018 | 1559 | 0.080 |
Why?
| | Minimally Invasive Surgical Procedures | 2 | 2008 | 192 | 0.080 |
Why?
| | Colorado | 2 | 2018 | 4562 | 0.080 |
Why?
| | Abdominal Abscess | 1 | 2009 | 25 | 0.070 |
Why?
| | Colonography, Computed Tomographic | 1 | 2009 | 8 | 0.070 |
Why?
| | Risk Assessment | 4 | 2016 | 3637 | 0.070 |
Why?
| | Intestinal Perforation | 1 | 2008 | 44 | 0.070 |
Why?
| | Capsule Endoscopy | 1 | 2008 | 25 | 0.070 |
Why?
| | Decompression, Surgical | 1 | 2009 | 115 | 0.070 |
Why?
| | Prognosis | 3 | 2016 | 4278 | 0.070 |
Why?
| | Gastric Mucosa | 1 | 2008 | 52 | 0.070 |
Why?
| | Duodenum | 1 | 2008 | 77 | 0.070 |
Why?
| | V-Set Domain-Containing T-Cell Activation Inhibitor 1 | 1 | 2008 | 6 | 0.070 |
Why?
| | Tissue Fixation | 1 | 2008 | 36 | 0.070 |
Why?
| | NAD(P)H Dehydrogenase (Quinone) | 1 | 2008 | 34 | 0.070 |
Why?
| | Palliative Care | 2 | 2009 | 996 | 0.070 |
Why?
| | Equipment Safety | 4 | 2008 | 38 | 0.070 |
Why?
| | Wounds, Penetrating | 1 | 2008 | 72 | 0.070 |
Why?
| | Immunoenzyme Techniques | 1 | 2008 | 200 | 0.070 |
Why?
| | Balloon Occlusion | 1 | 2008 | 39 | 0.070 |
Why?
| | Medical Records Systems, Computerized | 1 | 2008 | 95 | 0.070 |
Why?
| | Coloring Agents | 1 | 2007 | 93 | 0.060 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2008 | 141 | 0.060 |
Why?
| | Image Enhancement | 1 | 2008 | 199 | 0.060 |
Why?
| | Rectal Neoplasms | 1 | 2008 | 156 | 0.060 |
Why?
| | Duodenoscopy | 1 | 2006 | 8 | 0.060 |
Why?
| | Liver | 2 | 2005 | 1884 | 0.060 |
Why?
| | Laser Coagulation | 1 | 2006 | 77 | 0.060 |
Why?
| | Prosthesis Design | 2 | 2009 | 354 | 0.060 |
Why?
| | Intestinal Mucosa | 2 | 2008 | 676 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2730 | 0.060 |
Why?
| | Anesthesia, General | 1 | 2006 | 118 | 0.060 |
Why?
| | Operative Time | 1 | 2026 | 175 | 0.060 |
Why?
| | Radiation Exposure | 1 | 2026 | 63 | 0.060 |
Why?
| | Ascites | 1 | 2005 | 49 | 0.060 |
Why?
| | Thoracic Neoplasms | 1 | 2005 | 39 | 0.060 |
Why?
| | Acute Disease | 1 | 2008 | 1028 | 0.060 |
Why?
| | Administration, Rectal | 1 | 2024 | 13 | 0.050 |
Why?
| | Equipment Failure | 1 | 2005 | 115 | 0.050 |
Why?
| | Growth Substances | 1 | 2004 | 140 | 0.050 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2013 | 222 | 0.050 |
Why?
| | Pain Management | 1 | 2008 | 405 | 0.050 |
Why?
| | Immunoglobulin A | 1 | 2005 | 214 | 0.050 |
Why?
| | Liver Cirrhosis | 1 | 2006 | 288 | 0.050 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2013 | 419 | 0.050 |
Why?
| | Infant | 1 | 2018 | 10022 | 0.050 |
Why?
| | International Cooperation | 2 | 2017 | 197 | 0.050 |
Why?
| | Child, Preschool | 1 | 2018 | 11774 | 0.050 |
Why?
| | Neoplasm Metastasis | 1 | 2005 | 688 | 0.050 |
Why?
| | Diagnostic Tests, Routine | 1 | 2003 | 108 | 0.050 |
Why?
| | Necrosis | 1 | 2023 | 244 | 0.050 |
Why?
| | Pilot Projects | 1 | 2008 | 1867 | 0.050 |
Why?
| | Odds Ratio | 2 | 2016 | 1072 | 0.040 |
Why?
| | Combined Modality Therapy | 3 | 2013 | 1264 | 0.040 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2004 | 235 | 0.040 |
Why?
| | Anti-Infective Agents, Local | 1 | 2021 | 40 | 0.040 |
Why?
| | Disease-Free Survival | 2 | 2013 | 768 | 0.040 |
Why?
| | Drug Combinations | 1 | 2020 | 390 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 2025 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 2 | 2013 | 964 | 0.040 |
Why?
| | Myotomy | 1 | 2018 | 15 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2018 | 71 | 0.030 |
Why?
| | Republic of Korea | 1 | 2017 | 41 | 0.030 |
Why?
| | Endoscopic Mucosal Resection | 1 | 2018 | 38 | 0.030 |
Why?
| | Surgical Instruments | 1 | 2018 | 51 | 0.030 |
Why?
| | Administration, Oral | 1 | 2020 | 847 | 0.030 |
Why?
| | Bile | 2 | 2009 | 26 | 0.030 |
Why?
| | Autopsy | 1 | 2017 | 94 | 0.030 |
Why?
| | Surgery, Computer-Assisted | 1 | 2018 | 84 | 0.030 |
Why?
| | Prosthesis Failure | 2 | 2009 | 125 | 0.030 |
Why?
| | Colonic Polyps | 1 | 2018 | 85 | 0.030 |
Why?
| | Cytokines | 1 | 2004 | 2061 | 0.030 |
Why?
| | United Kingdom | 1 | 2017 | 336 | 0.030 |
Why?
| | Videotape Recording | 1 | 2016 | 37 | 0.030 |
Why?
| | Gastroenterologists | 1 | 2016 | 21 | 0.030 |
Why?
| | Hospitalization | 1 | 2006 | 2424 | 0.030 |
Why?
| | Geriatric Assessment | 1 | 2017 | 231 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2018 | 335 | 0.030 |
Why?
| | Barrett Esophagus | 1 | 2018 | 165 | 0.030 |
Why?
| | Radiologists | 1 | 2016 | 60 | 0.030 |
Why?
| | Watchful Waiting | 1 | 2016 | 88 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2008 | 6021 | 0.030 |
Why?
| | Phantoms, Imaging | 1 | 2016 | 158 | 0.030 |
Why?
| | Disease Management | 1 | 2018 | 643 | 0.030 |
Why?
| | Societies, Medical | 2 | 2008 | 886 | 0.030 |
Why?
| | Inflammatory Bowel Diseases | 1 | 2018 | 365 | 0.020 |
Why?
| | Organoplatinum Compounds | 1 | 2013 | 66 | 0.020 |
Why?
| | Injections, Intralesional | 1 | 2013 | 36 | 0.020 |
Why?
| | Leucovorin | 1 | 2013 | 101 | 0.020 |
Why?
| | Erlotinib Hydrochloride | 1 | 2013 | 72 | 0.020 |
Why?
| | Program Evaluation | 1 | 2017 | 946 | 0.020 |
Why?
| | Camptothecin | 1 | 2013 | 140 | 0.020 |
Why?
| | Comorbidity | 1 | 2017 | 1646 | 0.020 |
Why?
| | Treatment Failure | 1 | 2013 | 363 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 60 | 0.020 |
Why?
| | Quinazolines | 1 | 2013 | 266 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2011 | 121 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2013 | 778 | 0.020 |
Why?
| | Colorectal Neoplasms | 1 | 2018 | 844 | 0.020 |
Why?
| | Neoadjuvant Therapy | 1 | 2013 | 462 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2017 | 2926 | 0.020 |
Why?
| | Stainless Steel | 1 | 2009 | 21 | 0.020 |
Why?
| | Hematoma | 1 | 2009 | 59 | 0.020 |
Why?
| | Alloys | 1 | 2009 | 38 | 0.020 |
Why?
| | Terminally Ill | 1 | 2009 | 41 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 354 | 0.020 |
Why?
| | Medical Laboratory Science | 1 | 2008 | 9 | 0.020 |
Why?
| | Rupture | 1 | 2008 | 91 | 0.020 |
Why?
| | Miniaturization | 1 | 2008 | 22 | 0.020 |
Why?
| | Ligation | 1 | 2008 | 92 | 0.020 |
Why?
| | Probability | 1 | 2009 | 308 | 0.020 |
Why?
| | Premedication | 1 | 2008 | 42 | 0.020 |
Why?
| | Capecitabine | 1 | 2008 | 57 | 0.020 |
Why?
| | Total Quality Management | 1 | 2008 | 56 | 0.020 |
Why?
| | Evaluation Studies as Topic | 1 | 2008 | 166 | 0.020 |
Why?
| | Forms and Records Control | 1 | 2008 | 20 | 0.020 |
Why?
| | Esophageal and Gastric Varices | 1 | 2008 | 36 | 0.020 |
Why?
| | Radiotherapy Dosage | 1 | 2008 | 289 | 0.020 |
Why?
| | Morbidity | 1 | 2008 | 323 | 0.020 |
Why?
| | Remission Induction | 1 | 2008 | 306 | 0.020 |
Why?
| | Safety Management | 1 | 2008 | 121 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2007 | 183 | 0.020 |
Why?
| | Diarrhea | 1 | 2008 | 192 | 0.020 |
Why?
| | Injections | 1 | 2007 | 196 | 0.020 |
Why?
| | Costs and Cost Analysis | 1 | 2007 | 218 | 0.020 |
Why?
| | DNA | 1 | 2013 | 1460 | 0.010 |
Why?
| | Survival Analysis | 1 | 2009 | 1382 | 0.010 |
Why?
| | Information Dissemination | 1 | 2008 | 220 | 0.010 |
Why?
| | Safety | 1 | 2007 | 355 | 0.010 |
Why?
| | Patient Selection | 1 | 2009 | 719 | 0.010 |
Why?
| | Prostheses and Implants | 1 | 2006 | 141 | 0.010 |
Why?
| | Receptors, Interleukin-8B | 1 | 2004 | 23 | 0.010 |
Why?
| | Obesity | 1 | 2018 | 3057 | 0.010 |
Why?
| | Esophagectomy | 1 | 2005 | 135 | 0.010 |
Why?
| | Recurrence | 1 | 2007 | 1134 | 0.010 |
Why?
| | Survival Rate | 1 | 2008 | 2088 | 0.010 |
Why?
| | Swine | 1 | 2006 | 831 | 0.010 |
Why?
| | Positron-Emission Tomography | 1 | 2005 | 323 | 0.010 |
Why?
| | Ischemia | 1 | 2004 | 421 | 0.010 |
Why?
| | Epithelial Cells | 1 | 2004 | 1125 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2004 | 4146 | 0.010 |
Why?
| | Biomarkers | 1 | 2008 | 4254 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2006 | 4556 | 0.010 |
Why?
| | Animals | 1 | 2006 | 38030 | 0.000 |
Why?
|
|
Shah's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|